Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5941 to 5955 of 7707 results

  1. NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine kinase inhibitors (afatinib, erlotinib and gefitinib) in EGFR mutation-positive locally advanced or metastatic NSCLC.

    Recommendation ID TA310/1 Question NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine

  2. NICE recommended further research to explore the impact of having experiences of patients having continuous infusion 5-FU and take into account the impact on quality of life. The potential consequences of introducing pharmacokinetic dose adjustment should also be explored.

    Recommendation ID DG16/4 Question NICE recommended further research to explore the impact of having experiences of patients having continuous

  3. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    Recommendation ID TA333/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks

  4. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, is collected for all people treated with sofosbuvir in the NHS.

    Recommendation ID TA330/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks

  5. NICE recommended that research should be carried out to determine the relationship between activity and prosthesis failure.

    Recommendation ID TA304/1 Question NICE recommended that research should be carried out to determine the relationship between activity

  6. NICE recommends further research to demonstrate the utility of the Sonoclot system in detecting, managing and monitoring haemostasis in cardiac surgery.

    Recommendation ID DG13/1 Question NICE recommends further research to demonstrate the utility of the Sonoclot system in detecting, managing

  7. NICE recommends further research to establish optimal target dose ranges for 5-FU plasma levels in people with head and neck cancer, stomach cancer and pancreatic cancer.

    Recommendation ID DG16/3 Question NICE recommends further research to establish optimal target dose ranges for 5-FU plasma levels in people

  8. NICE recommends further research to investigate the clinical effectiveness of the integrated sensor-augmented insulin pump therapy systems in younger children and pregnant women. No data are currently available for these subgroups and their inclusion in future studies is encouraged.

    Recommendation ID DG21/2 Question NICE recommends further research to investigate the clinical effectiveness of the integrated sensor-augmented